Sign In
Buy FULC
$3.58
-0.140 (-3.76%)
At Close: Jul 31, 2026
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 06'th Mar 2026
CAMBRIDGE, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
08:30am, Tuesday, 03'rd Mar 2026
CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules t
Fulcrum: Strong HbF Signal, Narrow TAM, Same 'Hold' Conclusion
11:10am, Thursday, 26'th Feb 2026
Fulcrum Therapeutics (FULC) pivots to pociredir for severe sickle cell disease after discontinuing losmapimod. Pociredir's Phase 1 PIONEER data shows 7/12 patients hitting the ≥20% HbF threshold, bu
Fulcrum Therapeutics, Inc. (FULC) Q4 2025 Earnings Call Transcript
03:28pm, Tuesday, 24'th Feb 2026
Fulcrum Therapeutics, Inc. (FULC) Q4 2025 Earnings Call Transcript
What's Going On With Fulcrum Therapeutics Stock Tuesday?
09:48am, Tuesday, 24'th Feb 2026
Fulcrum's new sickle cell trial data show higher hemoglobin levels and no serious safety concerns in sickle cell disease patients.
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025
07:01am, Tuesday, 24'th Feb 2026
― Announced positive 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ―
― Mean absolute fetal hemoglobin (HbF) increased by 12.2% (from 7.1% to 19.3%) at Week 12 (n=12), representing a rapid, robust, and clinically relevant response, with progression toward pan-cellular
CAMBRIDGE, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve t
Wall Street Analysts See a 75.71% Upside in Fulcrum Therapeutics (FULC): Can the Stock Really Move This High?
10:55am, Thursday, 12'th Feb 2026
The consensus price target hints at a 75.7% upside potential for Fulcrum Therapeutics (FULC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earni
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 06'th Feb 2026
CAMBRIDGE, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives o
Campbell & CO Investment Adviser LLC Takes Position in Fulcrum Therapeutics, Inc. $FULC
04:31am, Tuesday, 20'th Jan 2026
Campbell and CO Investment Adviser LLC acquired a new position in shares of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) during the third quarter, according to its most recent 13F filing with the Securit
Fulcrum Therapeutics, Inc. (FULC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
02:46pm, Wednesday, 14'th Jan 2026
Fulcrum Therapeutics, Inc. (FULC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 09'th Jan 2026
CAMBRIDGE, Mass., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives o
Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
08:00am, Wednesday, 07'th Jan 2026
CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve t
Contrasting Fulcrum Therapeutics (NASDAQ:FULC) & VistaGen Therapeutics (NASDAQ:VTGN)
01:44am, Wednesday, 07'th Jan 2026
Fulcrum Therapeutics (NASDAQ: FULC - Get Free Report) and VistaGen Therapeutics (NASDAQ: VTGN - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare
